MabVax Therapeutics Holdings Aktie [WKN DE: A2AQEQ / ISIN: US55414P5044]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu MabVax Therapeutics Holdings Inc

03.05.18		AudioEye Selected by International Luxury Brand Canali for Web Accessibility (PR Newswire)
15.03.18		MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
06.03.18		MabVax Therapeutics Regains Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement (PR Newswire)
28.02.18		MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
19.02.18		Lifshitz & Miller LLP Announces Investigation of A10 Networks, Inc., Aerohive Networks, Inc., Jacksonville Bancorp, Inc., Key Technology, Inc., MabVax Therapeutics Holdings, Inc., MetLife Inc. (PR Newswire)
15.02.18		MabVax Therapeutics Schedules Previously Announced 1-for-3 Reverse Stock Split to Regain Compliance with NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement (PR Newswire)
12.02.18		MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer (PR Newswire)
07.02.18		MabVax to Present at BIO CEO & Investor Conference (PR Newswire)
06.02.18		MabVax Therapeutics Closes $2.1 Million Private Placement Financing (PR Newswire)
01.02.18		Gum Disease Awareness Month Emphasizes Dangers of the Silent Killer (PR Newswire)
31.01.18		SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MabVax Therapeutics Holdings, Inc. (MBVX) (PR Newswire)
17.01.18		EIGR Disappoints, EXEL's CELESTIAL Excels, JUNO In CELG's Crosshairs? (RTTNews)
16.01.18		MabVax Therapeutics Holdings, Inc. Provides Business Strategy Update (PR Newswire)
20.12.17		MabVax Therapeutics Announces Completion of Enrollment and Initial Patient Dosing in an Expanded Cohort of the Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy (PR Newswire)
13.12.17		MabVax Therapeutics Announces Completion of Enrollment and Dosing in Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
01.12.17		MabVax Stockholders Approve Proposals at Special Meeting of Stockholders (PR Newswire)
22.11.17		MabVax Announces Adjournment of Special Meeting of Stockholders (PR Newswire)
16.11.17		MabVax Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Listing Requirements (PR Newswire)
13.11.17		MabVax Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting (PR Newswire)
31.10.17		MabVax Therapeutics Provides Update on the MVT-5873 Phase 1 Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference (PR Newswire)
26.10.17		MabVax Therapeutics to Present Three Posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
24.10.17		MabVax Therapeutics Expands Intellectual Property Estate by Filing a New Patent Application on its Fully-Human Antibody Discoveries (PR Newswire)
17.10.17		MabVax Therapeutics Holdings, Inc. Provides Corporate Overview and Business Outlook (PR Newswire)
12.10.17		ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus (RTTNews)
11.10.17		MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers (PR Newswire)
06.10.17		Bridgepoint Education Schedules Third Quarter 2017 Earnings Conference Call for October 25, 2017 (PR Newswire)
06.10.17		MabVax Stockholders Approve Remaining Proposal at Special Meeting of Stockholders (PR Newswire)
04.10.17		MabVax Stockholders Approve Proposals at Special Meeting of Stockholders (PR Newswire)
03.10.17		Novel Preclinical Studies with MabVax Therapeutics' HuMab-5B1 Antibody and HuMab-GD2 Antibodies Presented at the 2017 World Molecular Imaging Congress (PR Newswire)
12.09.17		MabVax Therapeutics Holdings, Inc. Announces $2.0 Million Registered Direct Offering (PR Newswire)
07.09.17		MabVax Therapeutics Holdings, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City (PR Newswire)
06.09.17		MabVax Therapeutics Engages Greenhill & Co. as Advisor for Exploring Strategic Alternatives (PR Newswire)
23.08.17		RARE Disappoints, NSPR Put On Notice, PMD Launches Synthetic Cannabinoids Test (RTTNews)
22.08.17		MabVax Therapeutics Holdings, Inc. Announces the Closing of $1.3 Million Registered Direct Offering and is Engaging an Advisory Bank to Explore Strategic Alternatives (PR Newswire)
14.08.17		MabVax Therapeutics Holdings, Inc. Announces Pricing of Registered Direct Offering (PR Newswire)
24.07.17		MabVax Therapeutics Board of Directors Authorizes the Company to Explore Strategic Alternatives (PR Newswire)
27.06.17		MabVax Therapeutics Commences Patient Dosing in MVT-1075 Radioimmunotherapy Phase 1 Clinical Trial for the Treatment of Pancreatic, Colon and Lung Cancers (PR Newswire)
14.06.17		MabVax Therapeutics Reports Positive Phase 1 Results for MVT-2163 ImmunoPET Imaging Agent (PR Newswire)
07.06.17		MabVax Therapeutics ImmunoPET Imaging Agent MVT-2163 to be Featured in Two Presentations at the 2017 SNMMI Annual Meeting (PR Newswire)
05.06.17		MabVax Therapeutics Phase I Trial Results of Antibody Therapy MVT-5873 for the Treatment of Advanced Pancreatic Cancer Presented at the 2017 ASCO Annual Meeting (PR Newswire)
25.05.17		MabVax Therapeutics to Present Phase I Clinical Trial Results of MVT-5873 for the Treatment of Advanced Pancreatic Cancer in Poster Presentation at the 2017 ASCO Annual Meeting (PR Newswire)
24.05.17		MabVax Therapeutics Reports First Quarter 2017 Operational and Financial Results (PR Newswire)
22.05.17		MabVax Therapeutics Announces the Closing of its $4.1 Million Public Offering (PR Newswire)
16.05.17		AKBA Abuzz, ANTH On Track For RESULT, IMUC Faces Cash Crunch, IONS Falls (RTTNews)
16.05.17		MabVax Therapeutics Announces $4.1 Million Public Offering (PR Newswire)
08.05.17		COEUR, PROJECT Womens Partner To Launch New Lifestyle Platform During Market In Las Vegas (PR Newswire)
05.04.17		MabVax Therapeutics Presents Two Posters at the American Association for Cancer Research (AACR) Annual Meeting on a Novel Radioimmunotherapy Treatment for Pancreatic Cancer (PR Newswire)
23.02.17		MabVax Therapeutics Announces FDA Authorization to Proceed with MVT-1075 in a Phase I Clinical Trial for the Treatment of Pancreatic Cancer (PR Newswire)
13.02.17		MabVax Therapeutics Studies Lead Investigational Drug MVT-5873 with Halozyme PEGPH20 (PR Newswire)
05.12.16		MabVax Therapeutics Expands Phase I Clinical Trial Investigation for Patients with Pancreatic Cancer to Include HonorHealth Research Institute (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple auf dem Weg zu 100 US-Dollar in 2025?

Krypto-Rekorde voraus: Wall Street sieht Bitcoin bei 200.000 US-Dollar

Ripple Kurs Prognose: 10 US-Dollar bis Ende des Jahres?

Starke Aussichten? So könnten sich die Magnificent 7-Aktien, inklusive NVIDIA, 2025 entwickeln

Trump ruft eigenen Krypto-Coin "$TRUMP" ins Leben - Kryptocoin auch für Melania

Rückgang bei Tesla-Optionen: Vorstände zahlen Millionen im Vergleich

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.01.2025 07:15
Kaufwert:	EUR
	Hinzufügen Speichern